Cara Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street to higher close as SpaceX, Super Micro boost AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Janney Cuts Price Target on Cara Therapeutics (CARA) as UP is Delayed
March 11, 2016 10:12 AM ESTJanney Capital maintained a Buy rating on Cara Therapeutics (NASDAQ: CARA), and cut the price target to $18.00 (from $23.00), following the company's 4Q earnings report and conference call. The most significant development on the call was the disclosure that its December 2015 meeting with the FDA regarding its effort to develop CR845 for UP. Janney thought... More



